Microvascular Dysfunction from Coronary AngioCT? Vascular Remodeling Tiff-Off

Angina Patients studied invasively will show a significant proportion of non-obstructive coronary artery disease (ANOCA). From this group, nearly 50% might present coronary microvascular dysfunction (CMD), characterized by reduced coronary flow reserve (CFR < 2.5). Two different CMD phenotypes have been identified, according to minimal microvascular resistance assessment: patients with functional CMD (with resting elevated blood flow, Rµ hip ≤ 470 UW) and those with structural CMD (with reduced hyperemic flow, Rµ hip > 470).

Both resting and hyperemic CMD can be assessed by continuous thermodilution, by measuring flow (Q) and microvascular resistance (expressed in Woods-WU). Flow and resistance are closely related with myocardial mass (MM) and vascular volume (VV).

Coronary angiotomography (CTA) can be used to quantify MM, VV and V/M relation parameters. Based on this, Collet et al. characterized ANOCA patients by measuring microvascular resistance and vascular remodeling and MM patterns with CTA. 

This was a single center study carried out at the OLV Clinique in Aalst (Belgium), including angina patients with ANOCA (defined as FFR > 0.75). Patients with cardiac function deterioration, chronic kidney disease, concomitant valve disease and micro-cardiomyopathies were excluded. 

Read also: ENVISAGE-TAVI AF Trial: What Anticoagulant Should We Use?

CT data showed vessel specific MM measurements, plaque volume, VV, lumen volume (VL), atheroma percentage and V/M index.  For invasive measurement, PressureWire X devices were used and data were obtained with CoroFlow CV System software.  

Resting measurements were obtained using 3 ml saline injections. To assess hyperemia, 12 mg. intracoronary papaverine was administered, together with injections and a continuous saline infusion. Both resting and hyperemic absolute coronary flow data were registered (Qrest and Qhiper), mean transit time, microvascular resistance (Rµ, WU), CFR and microvascular resistance reserve (MRR). 

The study included 153 patients with ANOCA, 85 had normal CFR (control group), 22 presented structural CMD, and 46 functional CMD. 41% were women, and CMD was more frequent in older patients with hypertension and diabetes. There were no differences in FFR between the different phenotypes; however, CFR and MRR were lower in patients with structural CMD. These presented 40% lower Qhiper vs control and functional patients. 

Read also: Evolution at 1 Year for the PARTNER 3 Mitral Valve-in-Valve Study.

There was a strong correlation between lumen volume (LV) and myocardial mass (MM) (r = 0.70 [CI95%: 0.58-0.79]; P < 0.001). Epicardial VL was 40% lower in patients with structural CMD vs control and functional patients. Also, VL significantly correlated with minimal microvascular resistance (r = -0.59 [CI95%: -0.45 a -0.71]; P < 0.001). V/M relation was significantly reduced in patients with structural CMD, mainly because of volume. After regression and adjustment, only lumen volume was independently associated with microvascular resistance, establishing a 591 mm³ VL cut off value for structural CMD detection, with 75% sensitivity and 81% specificity.

Conclusions

In patients with ANOCA, it was observed through CTA that vascular remodeling correlates with the structural CMD phenotype, characterized by low coronary flow reserve and elevated minimal microvascular resistance. These findings highlight the role of CT in the detection of microvascular disease. 

Original Title: Vascular Remodeling in Coronary Microvascular Dysfunction

Reference: Collet C, Sakai K, Mizukami T, Ohashi H, Bouisset F, Caglioni S, van Hoe L, Gallinoro E, Bertolone DT, Pardaens S, Brouwers S, Storozhenko T, Seki R, Munhoz D, Tajima A, Buytaert D, Vanderheyden M, Wyffels E, Bartunek J, Sonck J, De Bruyne B. Vascular Remodeling in Coronary Microvascular Dysfunction. JACC Cardiovasc Imaging. 2024 Aug 30:S1936-878X(24)00308-5. doi: 10.1016/j.jcmg.2024.07.018. Epub ahead of print. PMID: 39269414.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....